Interdisciplinary issue: Multiple aura continua coexisting with the antiphospholipid activity of homeostasis and the possibility of therapy with Levetiracetam and Sulodexide

Abstract

The antiphospholipid activity of hemostasis (APLAH) favours pathological blood clot organisation, endothelial dysfunction and bioenergetic hypoxia. The prevalence of epilepsies in patients with antiphospholipid syndrome (APS) is 8,6 % for adults. Hypoxia coexisting with antiphospholipid syndrome leads to the development of status epilepticus (SE) in 10–12 % of cases. The temporal form of focal epilepsy is the most common form, and it is characterised by significant polymorphism of clinical manifestations. Also, the variants of masked epilepsy (ME) occur in the form of aura continua (AC) — the status or auras without alteration of consciousness. 6 women aged between 40 and 68 years with prolonged somatosensorial aura had functional hyposplenism and lactic acidosis of blood. 2 of them also had hyperproduction of antiphospholipid antibodies. Based on the research results, it was found that Levetiracetam (Keppra) is the preferable medication among antiepileptic drugs (AED) in cases of temporal epilepsy (TE) resistant to therapy. At the same time, Sulodexide (Vessel Due F) proved to be an effective drug due to dominant microvasculature damage in patients with antiphospholipid syndrome. It has an antiplatelet effect, normalises the state of the endothelial tissue, has a profibrinolytic and antiatherogenic effect.